DUBLIN--(BUSINESS WIRE)--The "Global Hydroxychloroquine Drugs Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.
The global hydroxychloroquine drugs market is projected to grow at a CAGR of 3.08% to reach US$1,174.129 million by 2025, from US$978.745 million in 2019.
Rising prevalence of chronic rheumatoid conditions, malaria, and lupus among the individuals is pushing the demand for hydroxychloroquine drugs.
According to the World Health Organization (WHO), there are approximately 150 diseases or more that come under Rheumatic or musculoskeletal condition that are associated with different degrees of pain and is progressive in nature. They are also referred to as joint diseases, physical disability, spinal disorders, and some other conditions; they may be a result of trauma. Rheumatoid Arthritis, which is among one of the conditions under this category is a type of systemic disease that affects the joints, connective tissues, and muscles and shows a prevalence of about 0.1% to 0.3% and is more common in women and is found majorly in the developed countries. It mainly affects individuals between the ages of 20 and 40.
In addition, Malaria, which is another disease that is cured by dosing the affected patients, with hydroxychloroquine is also among the prevalent diseases in many regions in the world. According to the World Health Organization, Malaria is a disease that is caused by the transmission of Plasmodium parasites to humans by the Anopheles mosquito. There are approximately 200 million cases of malaria that are reported every year. In the year 2017, the number of reported cases was around 219 million.
Furthermore, according to the statistics presented by the Lupus Foundation of America, about 5 million individuals globally are suffering from some sort of lupus, out of which there are an estimated 1.5 million American individuals. Lupus is an increasingly common disease among the women that of childbearing age. But, the children, men, and teenagers are also likely to develop thus diseases. The symptoms that are associated with these diseases include pain, high fatigue levels, cognitive loss, physical impairment among other symptoms. Thus, these diseases are increasing there is a surging demand for hydroxychloroquine drugs and is bolstering the market growth over the forecast period. However, as the hydroxychloroquine drugs are not so effective on all types of malaria, it hampers the market growth to some extent.
An increasing number of cases of people infected with the Coronavirus owing to the COVID-19 pandemic and the use of Hydroxychloroquine as a possible cure to control the rate of spread is boosting the market growth.
The coronavirus pandemic has gripped the world economies and caused significant damage to the resources and medical supplies of the country, with huge financial deficits, rising number of deaths reported cases every day and economic slowdowns. Thus, there is a growing requirement by the healthcare sector to invest money and carry out research and development of new and effective drugs that can be used as a possible cure against the coronavirus. Therefore, there are a lot of clinical trials going on and a lot of investment has been put into the research of the use of Hydroxychloroquine, which is a primarily used for other purposes and diseases and belongs to a class of anti-malarial, but has shown potential of its use in the current COVID-19 scenario.
Key Topics Covered:
1. Introduction
1.1. Market Definition
1.2. Market Segmentation
2. Research Methodology
2.1. Research Data
2.2. Assumptions
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Hydroxychloroquine Drugs Market Analysis, by Application
5.1. Introduction
5.2. Rheumatoid Arthritis
5.3. Malaria
5.4. Others
6. Hydroxychloroquine Drugs Market Analysis, by End-User
6.1. Introduction
6.2. Hospitals and Clinics
6.3. Ambulatory Surgical Centres
6.4. Research Labs
7. Hydroxychloroquine Drugs Market Analysis, by Geography
7.1. Introduction
7.2. North America
7.2.1. North America Hydroxychloroquine Drugs Market, By Application, 2019 to 2025
7.2.2. North America Hydroxychloroquine Drugs Market, By End-User, 2019 to 2025
7.2.3. By Country
7.2.3.1. United States
7.2.3.2. Canada
7.2.3.3. Mexico
7.3. South America
7.3.1. South America Hydroxychloroquine Drugs Market, By Application, 2019 to 2025
7.3.2. South America Hydroxychloroquine Drugs Market, By End-User, 2019 to 2025
7.3.3. 2025
7.3.4. By Country
7.3.4.1. Brazil
7.3.4.2. Argentina
7.3.4.3. Others
7.4. Europe
7.4.1. Europe Hydroxychloroquine Drugs Market, By Application, 2019 to 2025
7.4.2. Europe Hydroxychloroquine Drugs Market, By End-User, 2019 to 2025
7.4.3. By Country
7.4.3.1. UK
7.4.3.2. Germany
7.4.3.3. France
7.4.3.4. Spain
7.4.3.5. Others
7.5. Middle East and Africa
7.5.1. Middle East and Africa Hydroxychloroquine Drugs Market, By Application, 2019 to 2025
7.5.2. Middle East and Africa Hydroxychloroquine Drugs Market, By End-User, 2019 to 2025
7.5.3. By Country
7.5.3.1. Saudi Arabia
7.5.3.2. United Arab Emirates
7.5.3.3. Israel
7.5.3.4. Others
7.6. Asia Pacific
7.6.1. Asia Pacific Hydroxychloroquine Drugs Market, By Application, 2019 to 2025
7.6.2. Asia Pacific Hydroxychloroquine Drugs Market, By End-User, 2019 to 2025
7.6.2.1. Japan
7.6.2.2. China
7.6.2.3. India
7.6.2.4. Others
8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. Company Profiles
9.1. Novartis AG
9.2. Sanofi
9.3. Amneal Pharmaceuticals LLC.
9.4. Prasco Laboratories
9.5. Dr. Reddy's Laboratories Ltd
9.6. McKesson Medical-Surgical Inc.
9.7. Laurus Labs Ltd.
9.8. Intas Pharmaceuticals Ltd.
9.9. Lupin Pharmaceuticals, Inc.
9.10. Mylan N.V.
For more information about this report visit https://www.researchandmarkets.com/r/kyxzcp
